CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Oxford Immunotec Global PLC (OLD) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Oxford Immunotec Global PLC (OLD)
143 Park Drive, Milton Park
Phone: +44 1235442780p:+44 1235442780 Abingdon, OX14 4SE  United Kingdom Fax: +44 1235442781f:+44 1235442781
This company was Merged or Acquired on 3/9/2021.
This company ceased filing statements with the SEC on 3/18/2021.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Oxford Immunotec Global PLC,is a diagnostics company. It is focused on developing and commercializing tests for under-served immune-regulated conditions. Its product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Tick-borne disease is the collective name for diseases passed to humans through the bite of an infected tick. Its diagnostic tests for tick-borne infections include multiple laboratory developed tests (LDTs). Its tick-borne disease tests utilize molecular methods (such as polymerase chain reaction) and techniques to prosecute the immune system. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202012/31/2019YesYes---

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
3845 Electromedical and electrotherapeutic apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Patrick J.Balthrop 63 7/1/2019 1/29/2016
Chief Executive Officer, Director Peter J.Wrighton-Smith 45 1/1/2002 1/1/2002
Chief Financial Officer Matthew T.McLaughlin 43 4/30/2019 4/30/2019
6 additional Officers and Directors records available in full report.

Business Names
Business Name
Boulder Diagnostics Europe GmbH
Boulder Diagnostics Inc.
Immunetics, Inc.
10 additional Business Names available in full report.

General Information
Number of Employees: 273 (As of 9/30/2020)
Outstanding Shares: 25,577,834 (As of 1/27/2021)
Shareholders: 8
Stock Exchange: NASD
Fax Number: +44 1235442781


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 31, 2023